No abstract

Our survival rate for infants with CDH has improved over the last ten years, and this improvement is associated with the use of new therapies such as HFOV, inhaled nitric oxide and sildenafil.

Introduction and objectivesLong-term coronavirus disease 2019 (COVID-19) sequelae have become an increasing concern, with persistent dyspnoea and fatigue being the most common and long-lasting symptoms reported. The aim of this study was to evaluate the functional status and respiratory function three months after discharge from an inpatient rehabilitation program. Materials and methodsThis was a prospective study including post-ICU COVID-19 survivors consecutively admitted to an inpatient and multimodal rehabilitation program in a rehabilitation center. Evaluation of functional status (brief balance evaluation systems test (brief-BESTEST), timed up and go (TUG) test, 1 min sit to stand test (1STST), 6 min walking test (6MWT)); respiratory muscle strength (maximum expiratory pressure (MEP), maximum inspiratory pressure (MIP)); cough effectiveness (peak cough flow (PCF)); and fatigue (fatigue assessment scale (FAS)) were assessed at admission (T0), discharge (T1), and three months after discharge (T2). ResultsA total of 36 patients were included. Between T1 and T2, there was a significant improvement in MEP (84.47±20.89 vs 97.23±24.63 cmH 2 O, p<0.001), PCF (367.83±117.24 vs 441.33±132.90 L/min, p=0.003), functional capacity (1STST (19.90±6.37 vs 23.13±6.07, p=0.004), and 6MWT (459.25±153.70 vs 500.00±163.74 meters, p=0.003)). No differences were seen in MIP, brief-BESTEST, or TUG. Patients presented a higher median final FAS score at T2 compared to T1: 21.50±5 vs 18.60±2.65, p=0.002. ConclusionsPost-ICU COVID-19 survivors admitted to an inpatient rehabilitation program maintained a good functional recovery at the three-month follow-up. Despite overall improvement, we found higher scores of FAS, suggesting worse fatigue levels.

The child and her father have both a heterozygote mutation factor V Leiden. We report two patients with severe SLE who were refractory to standard drug therapies and our aim was to evaluate the efficacy and safety with this monoclonal antibody. RITUXIMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS IN PEDIATRIC PATIENTSA 11-years old girl with SLE (cutaneous, musculoskeletal and renal disease), requiring steroids and cyclophosphamide therapy. At 17 years old, renal function decreased (Glomerulonephritis Class IV-Jansen 2004) and refractory pancytopenia leading to more aggressive therapy with steroids, intravenous Immuneglobulin and mycophenolate, without clinical or laboratory response. We decided to add rituximab, achieving satisfactory control of disease, without major side effects.A 13-years-old boy, with hemolitic-uremic syndrome and neurologic disease who was diagnosed SLE and antiphospholipid antibody syndrome. Conventional therapy (steroids, cyclophosphamide, Immunoglobulin, plasmapheresis) was not enough to control the disease and at last rituximab was introduced. A clinical and laboratorial improvement was achieved in 4 weeks after rituximab administration with remission of disease after 27 months.Our results suggest the security and efficacy of RTX when used in combination with other immunosuppressive therapies. However, further prospective trials in greater series of children are needed to confirm our results using RTX in monotherapy or co-therapy, and to evaluate adverse events. Results: 601 (15%) of 4113 urine cultures were positive. The most frequent isolates in the earlier and later periods were, respectively: E.coli (30% and 41%), Klebsiella spp (27% and 25%), P. aeruginosa (5% and 9%), P. mirabilis (7% and 7%) and Candida spp. (11% and 4%). In 2008, the resistance of E.coli was (in descending order): cotrimoxazole (68%), nalidixic acid (52%), cephalotin (30%), ciprofloxacin (15%) and nitrofurantoin (8%). When all pathogens are considered, the highest antimicrobial coverages would be reached by ciprofloxacin (88%, CI95%=83.4-91.6%) and nitrofurantoin (75%, CI95% = 68.6-80.5 %). 1010